Fewer than a tenth of individuals who could benefit from GLP-1 drugs like Wegovy have access to them, warns the global health agency as it issues its initial guidance on the medications.
With over a billion people worldwide now classified as obese, it is urging increased and just availability to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The new guidelines acknowledges that obesity is a long-term condition that can be managed with comprehensive and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant hurdles to broad availability to the injections that can help people shift considerable body mass, explains the organization.
Skinny Jab Scarcity
Even in the present best projected case, the production of such drugs would only suffice for approximately 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The recommendation calls on nations and manufacturers to widen availability, through strategies such as voluntary licensing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is due to expire in several nations in 2026.
The Way Weight-Loss Drugs Function
These medications mimick a natural hormone to reduce digestion speed, suppress the appetite and boost satiety so individuals eat less.
People usually see weight reduction after several weeks of starting on the once-weekly jabs.
Research points to users may see weight return a year later of halting the drug, as their typical hunger come back.
Being overweight or obese raises your risk for experiencing diseases, including type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity concerns people in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, per the health agency.
